1. Kasai S, Arimura H, Nishida M, Suyama T. Primary structure of single-chain pro-urokinase. J Biol Chem 1985;260:12382–12389PMID : 2931434.
2. Harvey SR, Lawrcncc DD, Madeja JM, Abbey SJ, Markus G. Secretion of plasminogon activators by human colorectal and gastric tumor explants. Clin Exp Metastasis 1988;6:431–450PMID : 3409559.
3. Grondahl-Hansen J, Ralfkiaer E, Kirkeby LT, Kristensen P, Lund LR, Dano K. Localization of urokinase-type plasminogcn activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 1991;138:111–117PMID : 1702928.
4. Michalopoulos GK, Zarnegar R. Hepatocyte growth factor. Hepatology 1992;15:149–155PMID : 1530787.
5. Rubin JS, Bottaro DP, Aaronson SA. Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochem Biophys Acta 1993;1155:357–371PMID : 8268192.
6. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, van de Woude GF. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984;311:29–33PMID : 6590967.
8. Ponzetto C, Giordano S, Peverali F, Della Valle G, Abate ML, Vaula G, Comoglio PM. c-Met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene 1991;6:553–559PMID : 1674365.
9. Markus G, Takita H, Camiolo SM, Corasanti JG, Evers JL, Hobika G. Content and characterization of plasminogen activators in human lung tumors and normal lung tissue. Cancer Res 1980;40:841–848PMID : 7193515.
10. Sappino AP, Busso N, Belin D, Vassalli JD. Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinoma. Cancer Res 1987;47:4043–4046PMID : 2440556.
11. Markus G, Camiolo SM, Kohga S, Madeja J, Mittelman A. Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors. Cancer Res 1983;43:5517–5525PMID : 6193874.
12. Hearing VJ, Law LW, Corti A, Appella E, Blasi F. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 1988;48:1270–1278PMID : 2963689.
16. Lee KH, Hyun MS, Kim JR. Invasion-metastasis by hepatocyte growth factor/c-Met signaling concomitant with induction of urokinase plasminogen activator in human pancreatic cancer: role as therapeutic target. Cancer Res Treat 2003;35:207–212.
17. Nakamura T, Mawa K, Ichihara A, Kaise N, Nishino T. Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett 1987;224:311–316PMID : 3319692.
18. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, van de Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802–804PMID : 1846706.
19. Iyer A, Kmiecik TE, Park M, Daar I, Blair D, Dunn KJ, Sutrave P, Ihle JN, Bodescot M, van de Woude GF. Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene. Cell Growth Differ 1990;1:87–95PMID : 2085463.
20. Bellusci S, Moens G, Gaidomp G, Comoglio P, Nakamura T, Thiery JP, Jouanneau J. Creation of a hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene 1994;9:1091–1099PMID : 8134112.
21. Johnson M, Koukoulis G, Kochhar K, Kubo C, Nakamura T, Iyer A. Selective tumorigenesis in non-parenchymal liver epithelial cell lines by hepatocyte growth factor transfection. Cancer Lett 1995;96:37–48PMID : 7553606.
22. Jeffers M, Rong S, Anver M, van de Woude GF. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces trans-formation and the invasive /metastasic phenotype in C127 cells. Oncogene 1996;13:853–856PMID : 8761307.
24. Liotta LA, Rao CN, Barsky SH. Tumor invasion and the extra-cellular matrix. Lab Invest 1983;49:636–649PMID : 6317982.
25. Harvey SR, Lawrence DD, Madeja JM, Abbey SJ, Narkus G. Secretion of plasminogen activators by human colorectal and gastric tumor explants. Clin Exp Metastasis 1988;6:431–450PMID : 3409559.
28. Hollas W, Blasi F, Boyd D. Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res 1991;51:3690–3695PMID : 1648443.
29. Stahl A, Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994;54:3066–3071PMID : 8187097.
30. Heiss MM, Babic R, Allgaryer H, Gruetzner KU, Jauch KW, Loehrs U, Schildberg FW. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 1995;13:2084–2093PMID : 7636552.
31. Lee KH, Bae SH, Hyun MS, Kim SH, Song SK, Kim HS. Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer. Oncology 2004;66:210–217PMID : 15218312.
32. Mohanam S, Sawaya R, McCutcheon L, Ali-Osman F, Boyd D, Rao JS. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res 1993;53:4143–4147PMID : 8395977.
33. Okusa Y, Ichikura T, Mochizuki H, Shinomiya N. Urokinase type plasmingen activator and its receptor regulates the invasive potential of gastric cancer cell lines. Int J Oncol 2000;17:1001–1005PMID : 11029504.
34. Giehl K, Skripczynski B, mansard A, Menke A, Gierschik P. Growth factor dependent human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration. Oncogene 2000;19:2930–2942PMID : 10871844.
35. Kermorgant S, Aparicio T, Dessirier V, Vewin MJ, Lehy T. Hepatocyte growth factor induces colonic cancer cell invasivenss via enhanced motility and protease overproduction: evidence for PI3 kinase and PKC involvement. Carcinogenesis 2001;22:1035–1042PMID : 11408346.